Sander van Deventer is a founder and managing partner of Forbion Capital Partners. He serves as a non-‐executive on the boards of Argos Therapeutics, Inc., giCare Inc., Hookipa AG, uniQure NV and enGene, Inc. He also is a professor in Translational Gastroenterology at the University of Leiden and an accomplished scientist: He authored more 400 peer-‐review scientific papers and supervised more than 40 PhD students.
Sander van Deventer -‐a certified internist and gastroenterologist-‐ received his medical degree and doctorate (of philosophy) from the University of Amsterdam, after defending a thesis on the biological activities of bacterial lipopolysaccharides in humans. Following board certification in internal medicine and gastroenterology he worked as a scientist in the Laboratory for Medical Biochemistry, Rockefeller University, New York. He was the first to administer an anti-‐TNF monoclonal antibody (later registered as Remicade®) to patients with Crohn’s disease, the first to infuse apolipoprotein A1 in humans and had a critical role in the development of other therapeutic interventions, targeting cytokines, cytokine receptors, T-‐cells and signal transduction pathways, using small molecules, antibodies, peptides, proteins and antisense DNA technologies. He supervised the development of Glybera, the first gene therapy product to be approved in Europe, and several other gene therapy products. In 1995, he became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, and continued to work on therapeutic signal transduction inhibition, gene therapies, and (genetically engineered) probiotics. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam.
In 1998 he co-‐founded Amsterdam Molecular Therapeutics (AMT N.V.) currently uniQure B.V., developing AAV-‐based gene therapy products and now listed on Nasdaq, acting subsequently as CSO, CMO and CEO.
